Abstract Number: 680 • 2018 ACR/ARHP Annual Meeting
Unmet Needs in the Treatment of Ankylosing Spondylitis. a Long-Term Observational Study from a Single University Center
Background/Purpose: Despite the progress in the treatment of ankylosing spondylitis (AS), a significant number of patients does not achieve low disease activity (LDA). The aim…Abstract Number: 654 • 2017 ACR/ARHP Annual Meeting
Effect of Anti Tnfα Drugs on the Frequency of Circulating CD19+CD24hiCD38hi Breg Cells in Ankylosing Spondylitis
Background/Purpose: CD19+CD24hiCD38hi B cells demonstrate a regulatory capacity and their frequency is altered in the peripheral blood of patients with various autoimmune diseases. The pathogenic…Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting
In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…Abstract Number: 702 • 2016 ACR/ARHP Annual Meeting
Treatment with Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients with Ankylosing Spondylitis in a Large, Prospective Real-Life Cohort
Background/Purpose: We evaluated the effect of the anti-tumor necrosis factor (TNF) agents, golimumab (GLM) and infliximab (IFX), on healthcare resource utilization (HCRU) and work productivity…Abstract Number: 720 • 2016 ACR/ARHP Annual Meeting
Impact of HLA-B27 on Patient Profile and Treatment Response in As Patients Treated with Anti-TNF in Canadian Real-World
Background/Purpose: The human leukocyte antigen (HLA)-B27 allele is one of the strongest known genetic factors associated with the development of ankylosing spondylitis, however, previous studies…Abstract Number: 730 • 2016 ACR/ARHP Annual Meeting
Clinical and Quality of Life Improvements Observed with Golimumab and Infliximab in a Large Real-Life Ankylosing Spondylitis Population
Background/Purpose : We assessed baseline parameters associated with health-related quality-of-life (HRQoL) improvement in AS patients with anti-TNF treatment (golimumab [GLM]; infliximab [IFX; originator]) in the…Abstract Number: 1257 • 2016 ACR/ARHP Annual Meeting
Gender Differences in Ankylosing Spondylitis Patients Treated with Anti-TNF in Daily Practice with Ten Year Follow up
Background/Purpose: Anti-TNF treatment is available for Ankylosing Spondylitis (AS) for many years now, but the data on long term follow up in daily practice are…Abstract Number: 1258 • 2016 ACR/ARHP Annual Meeting
Female Gender Is Associated with a Poorer Response to TNF-Inhibitors in Ankylosing Spondylitis
Background/Purpose: Limited data is available on the influence of smoking, Body Mass Index (BMI) and gender on disease activity and response to TNF inhibitors in…Abstract Number: 2749 • 2016 ACR/ARHP Annual Meeting
Characteristics of Ankylosing Spondylitis Patients with Primary and Secondary Lack of Efficacy to TNF-Inhibitor Treatments
Background/Purpose: Anti-TNFi agents are effective in the treatment of active AS. Based on the available data, nearly 20% of the AS patients needed to switch…Abstract Number: 2837 • 2015 ACR/ARHP Annual Meeting
Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis
Background/Purpose: Anti-TNF agents are efficacious in the treatment of ankylosing spondylitis (AS). The switch to another TNF blockage can be an alternative in cases of…Abstract Number: 2555 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
Background/Purpose : The role of combined treatment with csDMARDs and anti-TNF therapy in AS is not well established. Methods: Main goal of this study was…Abstract Number: 2563 • 2014 ACR/ARHP Annual Meeting
The Distribution of Inflammatory Lesions in the Anterior and Posterior Structures of the Spine in Patients with Active Ankylosing Spondylitis and the Effect of TNF-α-Blockade
Background/Purpose Magnetic resonance imaging (MRI) is a key tool for the assessment of inflammatory lesions used for diagnosis and the monitoring of treatment effects in…Abstract Number: 957 • 2014 ACR/ARHP Annual Meeting
Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity?
Background/Purpose N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular risk with recent evidence that short-term inflammation control reduces its levels in ankylosing…Abstract Number: 851 • 2014 ACR/ARHP Annual Meeting
A Tailored Approach to Reduce Dose of Anti-TNF Drugs Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Propensity Score-Matched Cohort Study
Background/Purpose: To compare effectiveness, safety and costs of standard versus individually tailored reduced doses of anti-TNF drugs in patients with Ankylosing Spondylitis (AS) after achieving…Abstract Number: 2462 • 2013 ACR/ARHP Annual Meeting
Comparison Of Tumor Necrosis Factor Inhibitor Use For Ankylosing Spondylitis At University Rheumatology Clinics In Scotland and Oregon
Background/Purpose: Use of tumor necrosis factor inhibitors (TNFi) for ankylosing spondylitis (AS) is directed by national guidelines in the UK. However in the US, in…
ACR Meeting Abstracts